Q: How does Tesamorelin work?
A: It mimics the activity of naturally occurring GHRH. It signals the pituitary gland to release growth hormone, which also influences downstream IGF-1 levels.
Q: Is Tesamorelin the same as taking growth hormone?
A: No. it is not growth hormone itself. Instead, it stimulates the pituitary gland through GHRH receptors to increase endogenous growth hormone secretion.
Q: Why is Tesamorelin associated with visceral fat?
A: An FDA-approved tesamorelin product has been shown to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. That specific indication should not be interpreted to mean that compounded tesamorelin is FDA-approved for general abdominal fat reduction or weight management.
Q: Is Tesamorelin a weight-loss medication?
A: No. it should not be presented as a general weight-loss treatment. The FDA-approved tesamorelin labeling specifically states that it is not indicated for weight-loss management.
Q: Does Tesamorelin affect IGF-1?
A: Yes. By increasing growth hormone signaling, it can increase IGF-1. This is one reason appropriate medical evaluation and monitoring may be important during treatment.
Q: How long might Tesamorelin treatment continue?
A: Treatment duration is individualized. A period of several months may be used to evaluate response, tolerability, laboratory findings, and whether continued treatment remains appropriate.
